Table 2.
Phenotypic analysis of PBMC in the two groups of patients with BD in whom uveitis was either prevented or relapsed during and after the change from immunosuppressive drugs to p336–351-CTB tolerizing regime
| Uveitis not relapsed (n = 5) (mean ± sem) | Uveitis relapsed (n = 3) (mean ± sem) | |||||||
|---|---|---|---|---|---|---|---|---|
| After | After | |||||||
| Cell marker | Change | Before | 3 months† | 6–9 months‡ | Change | Before | 1–2 months | |
| Inverse relationship | ||||||||
| 1 | CD4 | Decrease | 37·3 (3·0) | 29·5 (3·7) | 22·0 (2·5)** | Increase | 28·6 (10·5) | 46·1 (12·7) |
| 2 | CCR5 | Decrease | 7·8 (1·8) | 4·0 (1·0)* | 3·8 (1·4) | Increase | 7·9 (2·2) | 10·2 (3·5) |
| 3 | CXCR3 | Decrease | 19·0 (4·3) | 12·5 (1·6) | 14·8 (4·1) | Increase | 14·4 | 26·6 |
| 4 | CCR7 | Decrase | 32·6 (6·6) | 31·8 (6·0) | 2·4 (1·0)* | Increase | 6·4 | 31·4 |
| 5 | CXCR4 | Decrease | 21·7 (5·9) | 23·1 (7·1) | 27·6 (3·1) | Decrease | 24·3 (15·6) | 5·1 (3·2) |
| 6 | CD28 | Decrease | 27·7 (10·4) | 14·3 (4·3) | 8·8 (2·8) | Increase | 30·1 (12·5) | 31·4 (15·7) |
| 7 | CD40 | Decrease | 42·2 (8·9) | 32·8 (4·6) | 19·8 (2·3)* | Increase | 25·3 (5·6) | 53·4 (9·4) |
| No inverse relationship | ||||||||
| 8 | TCR-γδ | Decrease | 5·0 (0·9) | 3·1 (1·1) | 4·3 (1·2) | No change | 2·9 (0·8) | 1·7 (0·7) |
| 9 | CCR6 | Decrease | 9·0 (1·8) | 3·7 (1·8) | 6·4 (1·3) | Nochange | 2·6 (0·4) | 1·5 (0·6) |
| 10 | CD86 | Increase | 9·6 (2·6) | 16·4 (2·1) | 11·6 (5·4) | Decrease | 4·5 (2·0) | 4·9 (3·0) |
†
at the end of tolerisation;
‡
3 patients who showed no relapse up to 10 months;
*
P = 0·05;
**
P = 0·01. CD8, CD45RA, CD45RO, CCR3 showed no distinguishing pattern.